Healthcare Fda Alzheimers Treatment News

FDA Delays Approval of Eli Lilly's Alzheimer's Drug, Stock Dips

The FDA has delayed its decision on Eli Lilly's experimental Alzheimer's treatment, donanemab, and plans to convene an advisory meeting to further review its safety and efficacy, reflecting the high stakes of developing treatments for Alzheimer's. The drug significantly slowed Alzheimer's progression in a late-stage trial, but carries safety concerns related to brain swelling and bleeding. This setback comes as Eli Lilly races to compete with Biogen and Eisai, who won approval for their Alzheimer's treatment, Leqembi, last year. Eli Lilly expressed confidence in donanemab's potential benefits and will work with the FDA and stakeholders to address concerns.